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mendations. Modifications incorporated into the study in-
cluded a stand-by balloon blocker placed into the main bron-
chus during every procedure and the repeat Doppler scanning
of the passages created and dilated by the needle–balloon
device before deploying the stent.
The present study was designed to demonstrate the ap-
plicability of airway bypass to a multicenter study and proof
of concept of the airway bypass procedure using the
paclitaxel-eluting stent in subjects with moderate-to-severe
emphysema. The subjects in this study had more severe
disease (greater RV and TLC, shorter 6MW, less quality of
life, and a higher percentage of homogeneous emphysema,
94% vs 46%, respectively) than those in the NETT. By
retrospective analysis, the most statistically significant re-
sults were observed in patients with the greatest degree of
pretreatment hyperinflation.
In conclusion, early results of the airway bypass proce-
dure using a paclitaxel-eluting stent in a multicenter study
have been shown to reduce hyperinflation and dyspnea and
to improve pulmonary function in subjects with severe
emphysema, especially in those with severe hyperinflation.
The clinical improvements demonstrated in these prelimi-
nary clinical results support further investigation of the
airway bypass procedure. Questions about patient selection,
the optimal placement of the stents, and stent patency pro-
vide direction for further study.
We acknowledge Joel D. Cooper, MD, Julia S. Rasor, MS, and
Terese Bogucki for analysis and peer review of this manuscript,
Peter Macklem, MD, Bonnie Stearns, and Corey Powell for the
statistical analysis, the Broncus staff, and Broncus Technologies
for sponsoring this study and for providing the equipment and
technical support.
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Discussion
Dr Cliff K. Choong (Cambridge, United Kingdom). Dr Cardoso,
congratulations to you and your co-investigators on this study and
results. I am glad to see that the good feasibility and safety results
that were found in the animal studies that we had performed have
been largely translated and reproduced by you and your clinical
investigators in this multicenter study. In the animal study that we
had performed at Washington University, we had found that 65%
of paclitaxel stents were patent at 18 weeks whereas the control
stents were all occluded at 4 weeks. This information was pre-
sented in 2005 before this Association and published in the Janu-
ary 2006 issue of the Journal of Thoracic and Cardiovascular
Surgery. I have always been curious about patency in clinical
studies on patients. On the one hand, it may be that ventilation
through the airway bypass stents between the airway and the
destroyed emphysematous lungs may improve the patency rate, but
on the other hand, thick mucus and infection in patients with
COPD may accelerate occlusions of the airway bypass stents. Did
you and your investigators assess the patency of the airway bypass
stents in your patients? If you did, what were the percentage of
patency and the duration of patency, and how did that correlate
with the clinical findings?
Second, have you any idea as to what may be the optimal
number of stents for treating patients with homogenous emphy-
sema?
The last issue concerns collateral ventilation. It seems to me
that the 1-way valve such as those produced by Emphasys and
Spiration may be useful in patients with minimal or no collateral
ventilation and causing atelectasis of the segments or lobes in
those areas, whereas the airway bypass stents may be effective and
useful in patients with extensive collateral ventilation. I think there
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may be a role in combining both modalities. I would appreciate
your opinion on that.
Dr Cardoso. Thank you very much, Dr Choong, and thanks for
the major contribution you have made. You paved the ground for
this clinical study to be done today with your animal data.
Regarding the number of stents, we participated in three dif-
ferent arms of this protocol, and this is the last arm. At the
beginning, the idea was to insert as many stents as possible. In a
few patients in whom we could not insert many stents owing to
anatomic reasons or for the presence of vessels around the airway,
we realized that these patients did as well as the patients who had
received many stents. We then concluded that perhaps it is not
necessary to use too many stents to get results. It became clear that
what is really necessary is to deflate both lungs.
Regarding patency, unfortunately I cannot provide this infor-
mation right now because this study is still ongoing. We will have
the data on patency when the study is completed in a few months.
What I have is anecdotal data on the last 2 patients on whom we
did the 6-month follow-up—the last 2 patients we treated in this
protocol. One of them had the stents completely open, whereas the
other patient had all the stents closed. We are still trying to figure
out which factors play a role in stent patency.
Regarding collateral ventilation and its effects, these are dif-
ferent things. The valve system and the stents work in different
emphysema patients. If we are talking about homogenous emphy-
sema with very severe destruction in the parenchyma, then these
are probably not the best patients for the valves but for the stents.
Since emphysema is generally a very heterogeneous population,
those patients who do have destruction, for example, in the upper
lobes with target areas could be treated with valves in the upper
lobes and the rest of the parenchyma could be treated with stents.
Time will tell about the outcome.
Dr Erino Rendina (Rome, Italy). Again, congratulations, Dr
Cardoso, on an excellent presentation. These are, to the best of my
knowledge, the first clinical results published on airway bypass.
You are to be congratulated on being able to demonstrate benefits
to this procedure at intervals as long as 6 months. I would like to
ask your opinion on two issues. The first issue is the selection
process. I did not see in your presentation anything about the
evaluation of the small airway in these patients. I think the status
of the small airway is a very important issue because it has a
relation with the destructive component of emphysema. Would
you like to comment on that?
The other issue is the deaths that occurred among your patients.
That stresses an important point. The airway bypass is a surgical
procedure. In our early experience with airway bypass at the time
when the stents were not available, we also had an episode of
bleeding, but we were able as surgeons to control this very serious
occurrence, and the patient had no problems. I think it is important
to keep in mind that, though safe, this remains a surgical procedure
that should be performed by surgeons.
Dr Cardoso. Thank you very much. Dr Rendina is another
cornerstone of this procedure.
Regarding selection, patients who have severe bronchitis prob-
ably are not the best candidates. As a matter of fact, we had 1
patient whose airway was so severely deranged because of bron-
chitis that we could not insert any stents. Furthermore, distal
airway disease is something that could eventually alter this mech-
anism by which airway bypass works, which is ultimately depen-
dent on the enhancement of collateral ventilation. I think one must
be very selective to get good results.
Regarding expertise, I think surgeons and pulmonologists who
can treat massive hemoptysis can do this procedure. That is not an
issue. The issue is that this has to be done in a surgical environ-
ment with all the equipment needed because it is an invasive
procedure and must be done by people who are very familiar with
interventional endoscopy. The regular diagnostic endoscopist
probably needs a lot of training to do this procedure safely.
Nonetheless, it is a rather straightforward and very safe procedure.
Dr John D. Puskas (Atlanta, Ga). Thank you, Dr Cardoso, for
your landmark study and congratulations on demonstrating for the
first time in a clinical trial the benefit of endoscopic airway
stenting.
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